Clinical Trial Detail

NCT ID NCT02558894
Title Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors NCT02558894
Indications

pancreatic ductal carcinoma

Therapies

Durvalumab

Tremelimumab

Age Groups: adult

No variant requirements are available.